4Bematsky S, Boivin JF, Joseph L, et al. An international cobort study of cancer in systemic lupus erythematosus [ J ]. Arthritis Rheum, 2005 ;52 : 1481-90.
5Chun BC, Bae SC. Mortality and cancer incidence in Korean patients with systemic lupus efythematosus: resuhs from the Hanyang lupus cohort in Seoul Korea[ J]. Lupus ,2005 ; 14:635-8.
4Hoffman RW.T cells in the pathogenesis of systemic lupus erythematosus.Clin Immunol,2004,113:4-13.
5Wouters CH,Diegenant C,Ceuppens JL,et al.The circulating lymphocyte prefiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship.Br J Dermatol,2004,150:693-700.
6Anand A,Dean GS,Quereshi K,et al.Characterization of CD3+ CD4-CD8 (double negative) T cells in patients with systemic lupus erythematosus:activation markers.Lupus,2002,11:493-500.
7Su CC,Shau WY,Wang CR,et al.CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity.Lupus,1997,6:449-454.
8Hochberg MC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum,1997,40:1725.
9Bombardier C,Gladman DD,Urowitz MB,et al.Derivation of the SLEDAI--a disease activity index for lupus patients:the Committee on Prognosis Studies in SLE.Arthritis Rheum,1992,35:630-640.
10Crispin JC,Martinez A,de Pablo P,et al.Participation of the CD69 antigen in the T-cell activation process of patients with systemic lupus erythematosus.Scand J Immunol,1998,48:196-200.
